Savings Experiment: Snow Removal
Why Your 2012 Tax Bill May Jump By $8,000
Pfizer (PFE) was the darling of the 1990s. Well, so was Bill Clinton, and like Clinton, the company pops up now and again in the news, but none of it really matters.
Pfizer's premier product, Lipitor, comes off patent this year and will get hit by generic competition in 2011. This drug has $11 billion in sales, which will shrink to $4 billion or less, and with that could go $5 billion or so in profits.
Pfizer has nothing in its pipeline to replace even a fraction of that revenue. Other drugs are coming off patent, and the stock is being held up by hope and an excessive dividend, which I believe will be cut in 18 to 24 months. Stay away.
At the time of this writing, the author did not own shares of PFE.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
Reader Comments (Page 1 of 1)
3-20-2010 @ 3:14PM
Blue Fox said...
I got rid of Pfizer when it was 36.00. Thank goodess. It has gone down hill ever since.